The centre will get new instrumentation for automated sampling and to set up advanced diagnostic workflows to drive innovation across industry, research and medical settings.
Proteomics already has an expanding arsenal of precision diagnostics targeting areas of unmet need, developed from its proteomics research and powered by its cutting-edge Promarker platform. The standard protein blood test is behind the company’s PromarkerD test for diabetic kidney disease, PromarkerEso test for oesophageal cancer and PromarkerEndo diagnostic for early-stage endometriosis.
The tests detect protein biomarkers in a patient’s blood and present the results as a universal “traffic light” risk score – low, moderate or high – to indicate their likelihood of having the disease.
Through a 66 per cent-owned subsidiary with UWA, Proteomics has also developed a revolutionary stress test to track muscle damage in elite athletes and thoroughbred racehorses.
Just yesterday, Proteomics announced it had achieved its milestone first patent in Japan for its simple PromarkerEndo blood test, and it is preparing for the product’s international commercial roll-out.
Japan is the world’s fourth-largest healthcare market, and already widely uses in vitro diagnostics and precision medicine to customise treatments for patients, deliver better patient outcomes and lower clinical costs.
The company completed a $12 million capital raise early last month, via a heavily oversubscribed share purchase plan, to drive development and accelerate the launch of its current four diagnostic tests.
The share raise came after Proteomics topped up its coffers in December last year, with a $2.16 million research and development grant delivered via the federal government’s tax incentive program. Management said the R&D grant would likely be directed towards accrediting testing at its United States laboratory.
With a suite of diagnostics in place and regulatory applications loaded in key international jurisdictions, Proteomics is stepping ever closer to unlocking some lucrative revenue streams, while also delivering potentially life-changing benefits for patients, clinicians and the agricultural industry.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
